h1. Key information • Revenue up 15% (compared to 2014 figures excluding Testa) to €2.1bn. • EBITDA up 51% on a reported basis and 11% excluding scope effects. • Net operating profit up 18%. • Backlog up 9% to €31.2bn mainly due to the consolidation of concession assets. • €1.3bn gain on the sale of Testa. • 23% residual stake in Testa. • Deleveraging thanks to the Testa sale. • As expected impairment of Repsol stake (€373m, we expec
24 Nov 2015
Modest impairment of the Repsol stake
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Modest impairment of the Repsol stake
Sacyr SA (VHM:STU) | 0 0 2.6% | Mkt Cap: 1,382m
- Published:
24 Nov 2015 -
Author:
Felix Brunotte -
Pages:
4
h1. Key information • Revenue up 15% (compared to 2014 figures excluding Testa) to €2.1bn. • EBITDA up 51% on a reported basis and 11% excluding scope effects. • Net operating profit up 18%. • Backlog up 9% to €31.2bn mainly due to the consolidation of concession assets. • €1.3bn gain on the sale of Testa. • 23% residual stake in Testa. • Deleveraging thanks to the Testa sale. • As expected impairment of Repsol stake (€373m, we expec